Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR2325] to ErbB 3 (phospho Y1289) - BSA and Azide free
- Suitable for: ICC/IF, WB
- Reacts with: Human
Product nameAnti-ErbB 3 (phospho Y1289) antibody [EPR2325] - BSA and Azide free
See all ErbB 3 primary antibodies
DescriptionRabbit monoclonal [EPR2325] to ErbB 3 (phospho Y1289) - BSA and Azide free
This antibody only detects ErbB 3 phosphorylated on Tyrosine 1289.
Tested applicationsSuitable for: ICC/IF, WBmore details
Unsuitable for: Flow Cyt,IHC-P or IP
Species reactivityReacts with: Human
Synthetic peptide within Human ErbB 3 (phospho Y1289). The exact sequence is proprietary.
ab157376 is the carrier-free version of ab76469 This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.
Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Ab157376 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.
Maxpar® is a trademark of Fluidigm Canada Inc.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferConstituent: PBS
Concentration information loading...
Our Abpromise guarantee covers the use of ab157376 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use at an assay dependent concentration.|
|WB||Use at an assay dependent concentration. Detects a band of approximately 185 kDa (predicted molecular weight: 148 kDa).|
FunctionBinds and is activated by neuregulins and NTAK.
Tissue specificityEpithelial tissues and brain.
Involvement in diseaseDefects in ERBB3 are the cause of lethal congenital contracture syndrome type 2 (LCCS2) [MIM:607598]; also called Israeli Bedouin multiple contracture syndrome type A. LCCS2 is an autosomal recessive neurogenic form of a neonatally lethal arthrogryposis that is associated with atrophy of the anterior horn of the spinal cord. The LCCS2 syndrome is characterized by multiple joint contractures, anterior horn atrophy in the spinal cord, and a unique feature of a markedly distended urinary bladder. The phenotype suggests a spinal cord neuropathic etiology.
Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
Contains 1 protein kinase domain.
Developmental stageOverexpressed in a subset of human mammary tumors.
DomainThe cytoplasmic part of the receptor may interact with the SH2 or SH3 domains of many signal-transducing proteins.
modificationsLigand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase.
Cellular localizationSecreted and Cell membrane.
- Information by UniProt
- c erbB 3 antibody
- c erbB3 antibody
- Erb b2 receptor tyrosine kinase 3 antibody
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab157376 has not yet been referenced specifically in any publications.